logo_web
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet
✕
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet

“The increase in international competitiveness and digitalisation will require more investment to ensure that Spain remains at the forefront of biomedical R&D”

The Deputy Director General of Farmaindustria, Javier Urzay, recalls that this is a key moment to define the country’s strategy in research to face the new challenges of the NHS

The registration period for the 16th Annual Conference of Biomedical Research Technology Platforms, to be held in Madrid on 23 May, is now open

Source: farmaindustria.es

On 23 May, Madrid will host the 16th Annual Conference of Biomedical Research Technology Platforms, promoted by Farmaindustria’s Spanish Technology Platform for Innovative Medicines in collaboration with Fenin, Asebio, Veterindustria and Nanomed.

The meeting, which resumes its face-to-face format, will be held under the title Strategic priorities in biomedical research and will present regional, national, European and international initiatives that are being implemented in order to prepare our system for possible new pandemics, promote the transformation of the National Health System (NHS), innovation as the backbone of the production system and enhance the participation of patients throughout the process. And all on the basis of a greater boost to public-private collaboration and digitisation.

“Globally, the pharmaceutical industry is undergoing a major transformation thanks to scientific advances and technological developments that will allow it to continue developing effective medicines to prevent and treat both prevalent and rare diseases, improving health outcomes, social welfare and the economy. However, at the same time, the sector faces a series of challenges that require joint action, through public-private collaboration, to address the growing global competition with a clear shift of investment in R&D and production towards Asian countries, the need to combat antimicrobial resistance, as well as the urgency of incorporating the lessons learned from the Covid-19 crisis in the face of potential new pandemics,” explains Javier Urzay, Deputy Director General of Farmaindustria and co-chair of the Spanish Innovative Medicines Technology Platform (Plataforma Tecnológica Española Medicamentos Innovadores).

Spain has a top-level pharmaceutical industry based on solid foundations which, in collaboration with the other agents involved – authorities and regulators, healthcare professionals, research centres, hospitals and patients – has made it one of the world’s leading countries in clinical research. The keys to maintaining Spain’s leading role will be discussed at the May meeting in Madrid thanks to the participation of forty renowned experts in the field, such as the director of the Carlos III Health Institute, Cristóbal Belda, and the vice-rector of Science Policy at the Carlos III University (Madrid), Juan José Vaquero, among others.

“This is a key moment to establish the country’s strategy in biomedical research to face the new challenges aimed at developing advanced therapies, more precise medicines based on the use of data and new technologies, as well as a model of decentralisation and networked research,” says Urzay, who will moderate the symposium Strategy to maintain leadership in clinical research. “To do this, we must focus on providing the centres with infrastructures, technical and human resources to adapt to the new scientific and regulatory requirements and greater international competition. This increased competitiveness and digitisation will require more investment in infrastructure and resources to ensure that our country remains at the forefront of biomedical R&D,” he adds.

At the same time, another of the country’s challenges must be addressed: the promotion of preclinical and translational research with a focus on public-private collaboration for a better transfer between hospitals, public research centres and emerging companies towards the industrial sector, as will be analysed in another of the Conference’s colloquiums entitled Strategy for the promotion of collaboration in preclinical research.

Registration and all the information on the 16th Annual Conference of Biomedical Research Technology Platforms is available at this link, as well as the full programme. The meeting is exclusively face-to-face and will take place in the Rafael del Pino Auditorium in Madrid.

Related entries

2 October, 2023

Decentralisation of trials, networking and digitisation, proposals to improve patient participation in clinical research


Leer más
26 September, 2023

More than 120 molecules in Alzheimer’s research, the great hope for patients, families and society


Leer más
19 September, 2023

The pharmaceutical industry’s plan to expand clinical trials in primary care


Leer más

Recent Posts

  • Decentralisation of trials, networking and digitisation, proposals to improve patient participation in clinical research
  • More than 120 molecules in Alzheimer’s research, the great hope for patients, families and society
  • The pharmaceutical industry’s plan to expand clinical trials in primary care
  • Health commitment to the pharmaceutical industry’s Strategic Plan to avoid losing 8,000 million euros
  • Improving patient access to innovative medicines and boosting R&D and manufacturing in Spain are the main priorities of the pharmaceutical industry

Contacta con nosotros


Tfno: +34 955.77.67.67
Fax: +34 955.77.65.56
info@distefar.net


Distefar del Sur
Sede Central

Distefar del Sur S.L.
Av. Umbrete, 58,
41110 Bollullos de la Mitación, Sevilla

Sede Madrid

Calle de Zurbano, 45, 28010 Madrid

CENTRAL

Pol. PIBO. Avda. de Gines, 14
+34 955 776 767 /+34 692 454 913
41110 Bollullos de la Mitación (Sevilla)

DELEGACIÓN MADRID

+34 674 575 115
28010 Madrid

Enlaces de interés

  • Aviso Legal
  • Política de privacidad
  • Política de cookies
  • Contacto

© 2023 Distefar del Sur SL. Todos los derechos reservados. agencianodo.com

  • No translations available for this page
  • Contact
  • Private Zone
  • English

    [recaptcha]

    In accordance with the provisions of Regulation (EU) 2016/679 and Organic Law 3/2018 regarding Data Protection, we inform you that the data you provide in this form will be incorporated into a file owned by DISTEFAR DEL SUR, SL domiciled in the C / Umbrete 58, (Pol. Ind. Pibo), 41110 of Bollullos de la Mitación (Seville), in order to manage your request.

    In this regard, and if you wish to exercise your rights of access, rectification, cancellation, opposition, portability and limitation, please send a written communication to DISTEFAR DEL SUR, SL, to the address indicated above or to info@distefar.com, attaching copy of your National Identity Document or equivalent identification document.

    Basic information about Data Protection

     Epigraph

    Basic information Data Protection

    Responsable

    DISTEFAR DEL SUR, S.L.

    Purpose

    Process your inquiry / request
    Detailed information on Data Protection

    Legitimation

    Consent
    Detailed information on Data Protection

    Recipients

    It is not expected to carry out data communications to third parties, except legal obligation
    Transfers of data to third countries outside the European Union will not be carried out
    Detailed information on Data Protection

    Rights

    You have the right of access, rectification, deletion, portability of your data, as well as limitation or opposition to your treatment, as detailed in Detailed information on Data Protection

    Additional Information

    You can consult the additional and detailed information on data protection by clicking here Detailed information on Data Protection

    All the data requested / The fields marked with * in the form are mandatory, if not filled in DISTEFAR DEL SUR, S.L. will not be able to meet your request.